EMERSON SOARES BERNARDES

EMERSON SOARES BERNARDES

(Fonte: Lattes)

Resumo

Bachelor's at Farmácia from Universidade Federal de Ouro Preto (1998) and doctorate at Applied Imunology from Universidade de São Paulo (2004). Has experience in Medicine, acting on the following subjects: galectina-3, carboidratos, trypanosoma cruzi, carcinogênesis and macrophage. (Text obtained from the Currículo Lattes on October 8th 2021)

Possui graduação em Farmácia pela Universidade Federal de Ouro Preto (1998), mestrado e doutorado em Imunologia Básica e Aplicada pela Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (2004), com período de Doutorado Sanduíche pela Universidade da California, Davis, USA. Realizou pós-doutoramento durante o período de 2004 a 2008 pela Faculdade de Medicina da USP-Ribeirão Preto. Trabalhou como pesquisador contratado pelo Instituto de Patologia e Imunologia Molecular da Universidade do Porto - IPATIMUP em Portugal no período de 2008 a 2011. Retornou ao Brasil como pesquisador visitante na Faculdade de Medicina da USP - São Paulo (2011-2012) e foi posteriormente contratado como pesquisador no Instituto do Câncer do Estado de São Paulo (2012-2013). Coordenou um projeto Jovem Pesquisador financiado pela FAPESP (2012-2016 - Desenvolvimento e Produção de Radiofármacos Emissores de Pósitrons com Aplicações Diagnósticas em Oncologia) e está integrado como pesquisador Colaborador no Instituto de Pesquisas Energéticas e Nucleares (IPEN). Tem atuado na área da Glicobiologia, com ênfase na participação de proteínas ligantes de carboidratos em processos inflamatórios e no Câncer. Atualmente é professor do Programa de Pós-Graduação do IPEN-USP Tecnologia Nuclear - Aplicações, tem experiência na área de Radiofarmácia, com ênfase no desenvolvimento de Radiofármacos inéditos para diagnóstico e terapia em Oncologia. (Texto extraído do Currículo Lattes em 08 out. 2021)

Página do item completo

Resultados de Busca

Agora exibindo 1 - 6 de 6

Radioactive gold nanoparticles coated with BSA
2024 - BARBEZAN, ANGELICA B.; ROSERO, WILMMER A.A.; VIEIRA, DANIEL P.; RIGO, MARIA E.Z.; SILVA, GIOVANA D. da; RODRIGUES, ALEX A.; ALMEIDA, LUIS F. de; SILVA, FABIO F.A. da; RIVERA, ANDY G.; SILVA, NATANAEL G. da; BERNARDES, EMERSON S.; ZEITUNI, CARLOS A.; ROSTELATO, MARIA E.C.M.
Background: Nanotechnology has revolutionized medicine, especially in oncological treatments. Gold nanoparticles (AuNPs) stand out as an innovative alternative due to their biocompatibility, potential for surface modification, and effectiveness in radiotherapeutic techniques. Given that prostate cancer ranks as one of the leading malignancies among men, there's a pressing need to investigate new therapeutic approaches. Methods: AuNPs coated with bovine serum albumin (BSA) were synthesized and their cytotoxicity was assessed against prostate tumor cell lines (LNCaP and PC-3), healthy prostate cells (RWPE-1), and endothelial control cells (HUVEC) using the MTS/PMS assay. For in vivo studies, BALB/C Nude mice were employed to gauge the therapeutic efficacy, biodistribution, and hematological implications post-treatment with BSA-coated AuNPs. Results: The BSA-coated AuNPs exhibited cytotoxic potential against PC-3 and LNCaP lines, while interactions with RWPE-1 and HUVEC remain subjects for further scrutiny. Within animal models, a diverse therapeutic response was observed, with certain instances indicating complete tumor regression. Biodistribution data emphasized the nanoparticles' affinity towards particular organs, and the majority of hematological indicators aligned with normative standards. Conclusions: BSA-coated AuNPs manifest substantial promise as therapeutic tools in treating prostate cancer. The present research not only accentuates the nanoparticles' efficacy but also stresses the imperative of optimization to ascertain both selectivity and safety. Such findings illuminate a promising trajectory for avant-garde therapeutic modalities, holding substantial implications for public health advancements.
Plant-derived polyphenolic compounds
2023 - ROSALES, THIECLA K.O.; SILVA, FABIO F.A. da; BERNARDES, EMERSON S.; FABI, JOAO P.
Plant-derived polyphenols are naturally occurring compounds widely distributed in plants. They have received greater attention in the food and pharmaceutical industries due to their potential health benefits, reducing the risk of some chronic diseases due to their antioxidant, anti-inflammatory, anticancer, cardioprotective, and neuro-action properties. Polyphenolic compounds orally administered can be used as adjuvants in several treatments but with restricted uses due to chemical instability. The review discusses the different structural compositions of polyphenols and their influence on chemical stability. Despite the potential and wide applications, there is a need to improve the delivery of polyphenolics to target the human intestine without massive chemical modifications. Oral administration of polyphenols is unfeasible due to instability, low bioaccessibility, and limited bioavailability. Nano-delivery systems based on polysaccharides (starch, pectin, chitosan, and cellulose) have been identified as a viable option for oral ingestion, potentiate biological effects, and direct-controlled delivery in specific tissues. The time and dose can be individualized for specific diseases, such as intestinal cancer. This review will address the mechanisms by which polysaccharides-based nanostructured systems can protect against degradation and enhance intestinal permeation, oral bioavailability, and the potential application of polysaccharides as nanocarriers for the controlled and targeted delivery of polyphenolic compounds.
Selection of aptamers against the Jagged-1 protein
2022 - SILVA, F.F.A. da; SANTOS, S.N. dos; PEREIRA, J.P.M.; GUSHIKEN JUNIOR, D.S.; CARNEIRO, M.A.P.; NASCIMENTO, I.C.C.; ULRICH, A.H.; BERNARDES, E.S.
The breast cancer is one of the biggest public health problems in the world, being the main female type of cancer that affects the population. The Jagged-1 protein plays an important role in the biology and development of cancer, influencing angiogenesis, growth of neoplastic cells, tumor stem cells, epithelial mesenchymal transition, metastatic processes and resistance to therapies in various types of cancer. In this project, our aim was to select an aptamer for JAG1 ligand using an aptamer library that could be used as a radiopharmaceutical for PET/SPECT/CT diagnosis of tumors that express JAG1. Our work showed that MDA-MB-231-JAG1 cells overexpress more mRNA and JAG1 protein than control cells (MDA-MB-231-Control). We also selected aptamers with high affinity for MDA-MB-231-JAG1 cells that could be a useful tool for the development of new radiopharmaceuticals for the diagnosis and treatment of tumors that overexpress JAG1.
Uncovering the role of modified citrus pectin in cancer
2022 - SILVA, FABIO A. da; BERNARDES, EMERSON S.
Background: Modified citrus pectin (MCP) is a polysaccharide consisting of galacturonic acid with anti-cancer activity that can act synergistically with other treatments to reduce tumor growth, stimulate programmed cell death and reduce the number of metastases. In addition, MCP prevents acute and severe renal syndromes caused by radiation/chemotherapy. All of these effects were reported to be due to MCP ability to specifically inhibit Galectin-3 protein functions. Aims: The aim of this work was to evaluate the anticancer effect of MCP in a Balb/c nude mice xenograft model of ovarian cancer. Methods: The human ovary cancer cell line, SKOV-3, was subcutaneously injected in Balb/c nude mice and tumor growth was monitored daily with a caliper. When tumors reached 250-300 mm3, 20 mg/kl of MCP was administered intravenously (I.V.) in a daily based for 21 days. Tumor growth and mice weight were monitored daily. Additionally, MCP was radiolabeled with 99m-technetium (99m-Tc) with the incubation of MCP (2.5 mg) in saline with SnCl2 (4 mg/ ml), HCl (0.01 M), NaOH (0.01 M) and 99mTc (129,5 MBq) at pH=7 for 30 min. The radiochemical purity was determined by iTLC-SG with acetone and ethanol/NH3/H2O (1:2:5). 99mTc-MCP (37 MBq) was administrated I.V. in Balb/C nude mice bearing SKOV-3 tumors and after 1, 2 and 4 hours, SPECT/CT image was acquired (Albira SI Buker). Ex-vivo biodistribution studies were performed after the I.V. injection of 10 MBq of 99mTc-MCP for 1-hour. The % of injected dose per gram (%ID/g) of tissues of interest was calculated. The tumors were removed, fixed, cut and used for autoradiography studies and stained with hematoxylin and eosin (H&E) to verify hypoxic regions. Results: The I.V. administration of MCP was able to significantly reduce SKOV-3 tumor growth (52% tumor volume reduction) in comparison with the non-treated group, after 21 of treatment. Our biodistribution studies showed that 99mTc-MCP was mainly found in kidneys, bladder and liver of mice (%ID/g = 12.25, 38.57 and 5.71, respectively), and was able to reach the tumor (%ID/g = 0.765 ± 0.045) 1-hour after I.V. administration. 99mTc-MCP accumulation in the tumor site was visualized by μSPECT/CT imaging 1 hour after I.V. administration. The autoradiography and stained (H&E) study demonstrated a correlation between MCP and regions of tumor necrosis. Because of MCP high accumulation in kidneys, renal toxicity was also evaluated. We were able to find that MCP doesn’t induce renal toxicity when administered in a daily base at a concentration of 20 mg/Kg. Conclusion: In this work we demonstrated that a daily treatment of MCP was able to reduce tumor growth of ovarian tumor xenografts (SKOV-3 cells) without showing renal toxicity. We found too that MCP can reach the tumor site, binding mainly in regions of necrosis. However, other studies are needed to unravel the mechanisms of action that act on the antitumor effect of MCP.
Selection of aptamers against Jagged-1 protein
2021 - SILVA, F.F.A. da; SANTOS, S.N. dos; GUSHIKEN JUNIOR, D.S.; CARNEIRO, M.A.P.; BERNARDES, E.S.
Radiochemistry and pharmacokinetics of Pectin (MCP)
2020 - SILVA, FABIO F.A. da; SANTOS, SOFIA N. dos; PIJEIRA, MARTHA S.O.; BERNARDES, EMERSON S.